TL;DR
This study performed a network meta-analysis to compare the efficacy and safety of various immunosuppressive drugs for lupus nephritis (LN). While voclosporin combined with MMF showed the highest complete remission rates, it also carried a significantly higher risk of infection. Tacrolimus (TAC) emerged as a safer alternative, offering good efficacy with a lower risk of infection.
What Problem Does This Paper Address?
Systemic lupus erythematosus (SLE) is an autoimmune disease that frequently affects the kidneys, leading to lupus nephritis (LN). LN is a major cause of morbidity and mortality in SLE patients. Effective treatment of LN involves controlling kidney impairment, typically through induction therapy with immunosuppressive drugs. However, these drugs can suppress the immune system, increasing the risk of infections, which are a significant concern for LN patients. While several immunosuppressive agents are used, their comparative efficacy and safety, especially newer agents like voclosporin, are not always clear. This paper addresses the need for a comprehensive comparison of these treatments to guide clinical decision-making.
Methods
The researchers conducted a systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) investigating immunosuppressive induction therapy for LN. They followed PRISMA guidelines and registered their protocol. The search was performed across Web of Science, PubMed, and Embase databases, including studies published up to October 2023. The analysis focused on specific drugs: Voclosporin, Leflunomide, Azathioprine (AZA), Cyclosporine A (CSA), Tacrolimus (TAC), Mycophenolate mofetil (MMF), Cyclophosphamide (CYC), and Belimumab.
Key outcomes assessed were:
- Effectiveness: Complete renal remission (CR) and partial renal remission (PR).
- Safety: Incidence of infection and serious infection.
A random-effects model was used for the NMA, with odds ratios (OR) and 95% credible intervals (Crl) calculated to compare treatments. The GRADE method was employed to assess the confidence level of the evidence. Risk of bias was evaluated using the Corcoran risk assessment tool.
Datasets
The study utilized data from 17 published randomized controlled trials (RCTs) involving a total of 2444 patients with LN. No new datasets were created or introduced.
Key Insights and Ideas
- Voclosporin + MMF: Efficacy Champion, Safety Concern: This combination demonstrated the highest rates of complete renal remission (CR), making it highly effective in achieving kidney recovery. However, this comes at a significant cost: a markedly increased risk of infections, including serious ones.
- Tacrolimus (TAC): The Balanced Option: TAC emerged as a strong contender, offering good efficacy while maintaining a significantly lower risk of infection and serious infection compared to other agents. This positions TAC as a favorable choice when safety is a primary consideration.
- Belimumab + MMF: A Promising Combination: When combined with MMF, Belimumab showed a high treatment ranking, second only to voclosporin + MMF in terms of efficacy.
- Heterogeneity in Evidence: While the overall analysis provided valuable insights, the authors noted that the credibility of evidence for some outcomes, particularly for TAC, was rated as low due to factors like risk of bias and publication bias.
Key Results
- Complete Remission (CR): Voclosporin + MMF showed significantly higher CR rates compared to MMF, IVCY, low-dose Leflunomide, and Belimamab+MMF. TAC also demonstrated better CR than IVCY.
- Partial Remission (PR): No significant difference was found in PR rates between different treatment drugs.
- Infection Risk: MMF showed a significantly higher risk of infection compared to TAC. IVCY also had a significantly higher risk of serious infection compared to TAC. Voclosporin + MMF had the highest ranking for infection risk, though this increase did not reach statistical significance in the study.
- Safety Ranking (SUCRA): Voclosporin + MMF ranked highest for CR and PR, but also highest for infection and serious infection risk. TAC consistently ranked lowest for infection and serious infection risk.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Sizes and Limited RCTs: The number of included RCTs was relatively small, and some studies had limited sample sizes, which can impact the robustness of the findings.
- Lack of Direct Comparisons: The NMA relies on indirect comparisons, which are not a direct substitute for head-to-head RCTs.
- Focus on Specific Outcomes: The study's evaluation of efficacy and safety was limited to CR, PR, infection, and serious infection. Other adverse events were not included.
- Heterogeneity in Study Design: Factors such as dosing regimens, administered doses, and timing of experimental endpoints across studies could influence outcomes.
Future work could involve expanding the analysis to include other adverse events and conducting direct comparisons through more RCTs to further refine treatment recommendations. The authors also suggest caution in interpreting results due to the limitations, particularly regarding the confidence in the efficacy evaluation of TAC.
Summary updated